Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Quarterly Report · 10-Q

CapsoVision, Inc.

CVNASDAQEQUITYCurrent

Quarterly Report

Filed May 14, 2026Accepted May 14, 2026, 4:35 PM EDTCIK 1378325Accession 0001378325-26-000021
Share

Company context

We are a global commercial-stage medical technology company focused on creating diagnostic and screening products to identify abnormalities of the GI tract. We develop advanced imaging and AI technologies in creating such products while maximizing the flexibility, convenience, profitability, and safety of patient care. We are a Delaware company, incorporated in 2005. Our corporate headquarters is located in Saratoga, California.

Current securities

Recent company filings

  1. 10-Q filingNov 12, 2026
  2. Results of Operations and Financial ConditionNov 12, 2026
  3. SCHEDULE 13G/A - filed by HARARI ELIYAHOU ET AL regarding CapsoVision, IncNov 4, 2026
  4. Other EventsSep 28, 2026
  5. 4 filingSep 23, 2026

Registered securities in this filing

CAPSOVISION, INC. · 10-Q · Filed 2026-05-14

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

common stock, $0.001 par value per share

Symbol
CV
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: c-1

Dimensions: Not supplied

Accession 000137832526000021 · 1 registered-security cover member

Read the exact SEC filing ↗

As-filed source

Primary evidence

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.